イベルメクチン創薬(がん)
Ivermectin-Based Drug DiscoveryーCancer
- 専門分野
-
- 消化器癌
- 液体生検
- 低侵襲手術
近年、高度進行癌に対する拡大手術の効果が否定され、外科治療の低侵襲化と集学的治療の重要性が注目されています。薬物療法においても、治療薬に対する耐性の問題が依然として大きな課題です。こうした難治性癌への新たな治療法開発の一環として、私たちは山梨大学大村記念微生物資源研究フロウティラに参加し、イベルメクチン誘導体の研究に取り組んでいます。イベルメクチンは、近年の研究で細胞増殖や血管新生の阻害、多剤耐性株への効果といった抗腫瘍作用が報告され、免疫チェックポイント阻害剤との併用による相乗効果も示されています。北里大学ならびに山梨大学の研究基盤に、臨床現場の知識と経験を結集することで、新たな治療戦略の確立が期待されます。本プロジェクトを通じて、難治性癌への革新的なアプローチを推進し、次世代の医療創出に貢献してまいります。
In recent years, the effectiveness of extensive surgical procedures for advanced cancers has been increasingly questioned. As a result, there is growing emphasis on minimally invasive surgical techniques and the importance of multidisciplinary treatment approaches. Despite advances in pharmacotherapy, drug resistance remains a significant challenge in cancer treatment.
As part of efforts to develop novel therapeutic strategies for refractory cancers, researchers at the University of Yamanashi are participating in the Flotilla: Ōmura Memorial Research Organization, focusing on the study of ivermectin derivatives. Ivermectin has been reported to exhibit antitumor properties, including inhibition of cell proliferation and angiogenesis, as well as efficacy against multidrug-resistant cancer cells. Furthermore, recent studies have demonstrated synergistic effects when used in combination with immune checkpoint inhibitors.
By integrating the research foundations of Kitasato University and the University of Yamanashi with clinical expertise from the medical field, this collaborative initiative aims to establish innovative therapeutic strategies. Through this project, we are committed to advancing novel approaches to refractory cancers and contributing to the development of next-generation medical treatments.
